Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25110465 | 1.00 | EPHX2 (0.48) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25468398 | 1.00 | EPHX2 (0.48) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25468400 | 1.00 | EPHX2 (0.48) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL22790857 | 0.94 | KMT2A (0.47) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25108520 | 0.94 | KMT2A (0.47) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25109404 | 0.93 | EPHX2 (0.45) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25110485 | 0.93 | TSHR (0.49) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL24514526 | 0.93 | KMT2A (0.45) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL25109406 | 0.93 | TSHR (0.53) | EPHX2KMT2ALMNAMEN1ALDH1A1 | |
| SCHEMBL22794307 | 0.93 | EPHX2 (0.43) | EPHX2KMT2ALMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | EPHX2 3163/4885KMT2A 310/4885LMNA 980/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | EPHX2 2724/4885KMT2A 380/4885LMNA 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.